TORONTO, July 22 /CNW/ - Amorfix Life Sciences (TSX: AMF), a company focused on treatments and diagnostics for brain-wasting diseases and the University of British Columbia (UBC), today announced a research collaboration to develop Alzheimer’s treatments based upon the discovery of misfolded superoxide dismutase 1 (SOD1) protein in the brains of people with Alzheimer’s Disease. The research will be aimed at preclinical efficacy studies for both antibody treatments and vaccines and will be conducted in Dr. Cashman’s laboratory at the Brain Research Center at the UBC in collaboration with Amorfix scientists, and will be supported by a grant from the Canadian Institutes for Health Research (CIHR).
